Supernus Pharmaceuticals (SUPN) Long-Term Investments (2012 - 2024)

Supernus Pharmaceuticals (SUPN) has 13 years of Long-Term Investments data on file, last reported at $11.7 million in Q1 2024.

• On a quarterly basis, Long-Term Investments fell 78.47% year-over-year to $11.7 million in Q1 2024; TTM through Mar 2024 was $11.7 million, a 78.47% decrease from a year earlier, with the FY2023 full-year figure at $16.6 million, down 82.3% from the prior year.
• Long-Term Investments for Q1 2024 stood at $11.7 million, down from $16.6 million in the prior quarter.
• Over the last five years, Long-Term Investments for SUPN reached as high as $534.7 million in Q1 2020 and fell as low as $11.7 million in Q1 2024.
• Historically, Long-Term Investments has averaged $206.5 million across 5 years, with a median of $128.6 million in 2022.
• Across the five-year window, Long-Term Investments increased 4.46% in 2021 and sank 82.3% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $350.4 million in 2020, then slumped by 65.99% to $119.2 million in 2021, then decreased by 21.21% to $93.9 million in 2022, then sank by 82.3% to $16.6 million in 2023, then declined by 29.82% to $11.7 million in 2024.
• Per Business Quant data, the three most recent Long-Term Investments figures were $11.7 million in Q1 2024, $16.6 million in Q4 2023, and $25.1 million in Q3 2023.